Core Viewpoint - Globex Mining Enterprises Inc. is updating shareholders on exploration drilling by Cartier Resources Inc. on Globex's Nordeau Royalty claims, highlighting the discovery of a new gold zone called the East Nordeau Zone, which is part of an aggressive drilling program [1][2]. Group 1: Exploration and Drilling Results - Cartier Resources has reported significant high-grade gold mineralization in the East Nordeau Zone (ENZ), which consists of two parallel high-grade gold zones, EN1 and EN2, with a confirmed strike length of 400 meters and open to depth [2][4]. - The ENZ is located 800 meters south of the Contact Sector and the high-grade North Contact Zone, indicating potential for further gold discoveries in the Nordeau Sector [2][4]. - Notable drill results include: - CA25-565: 23.2 g/t Au over 1.0 meters in EN1 Zone - CA25-570: 11.9 g/t Au over 1.0 meters in EN1 Zone and 14.1 g/t Au over 1.0 meters in EN2 Zone - CA25-572: 7.3 g/t Au over 1.0 meters in EN1 Zone [5]. Group 2: Future Plans and Expectations - Cartier plans further drilling to refine the geological model and verify the continuity of mineralization, with exploration drilling aimed at testing several new high-priority regional targets along the Nordeau Sector and the Cadillac Fault Zone [4][9]. - The success of Cartier's drilling on Globex's royalty claims is viewed positively, with anticipation for additional results from the North Contact Zone and the East Nordeau Zone as the drilling program progresses [9].

Core Viewpoint - The Donerail Group expresses disappointment over MarineMax's lack of engagement regarding a cash acquisition proposal of $35 per share and urges shareholders to vote against CEO Brett McGill at the upcoming annual meeting as a call for a strategic review of the company [1][6][8]. Group 1: Acquisition Proposal - Donerail has proposed an all-cash acquisition of MarineMax at $35 per share, which represents a significant premium over the company's unaffected trading levels [3]. - The proposal was initially submitted on January 13, 2026, with a follow-up detailed proposal on February 1, 2026, but the MarineMax Board has not provided meaningful feedback or established a process to evaluate the proposal [4]. - Donerail remains prepared to finalize the proposal upon receiving access to necessary confidential information for due diligence, indicating a potential willingness to increase the offer price [5]. Group 2: Shareholder Engagement - There has been substantial engagement from shareholders and financial institutions expressing concerns about MarineMax's performance and governance, reinforcing the belief that the company's intrinsic value is not reflected in its current share price [6]. - The California State Teachers' Retirement System (CalSTRS) has voted against the re-election of CEO Brett McGill and other director nominees, signaling a growing recognition among institutional investors for the need for change at MarineMax [7]. - Levin Capital Strategies has also called for an immediate strategic review following Donerail's acquisition proposal, citing past failures of MarineMax leadership to capitalize on credible offers [7]. Group 3: Call to Action - Donerail urges shareholders to vote against CEO Brett McGill at the upcoming annual meeting to signal dissatisfaction with the current Board's approach and to advocate for better representation of shareholder interests [8]. - The increasing number of institutional investors voicing concerns highlights the urgent need for decisive action to ensure that shareholder interests are prioritized [8].

Core Insights - Palisade Bio, Inc. presented new translational data for PALI-2108, a targeted oral PDE4 inhibitor prodrug, at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, demonstrating localized target engagement and early clinical response within seven days [1][2][10] Group 1: Clinical Findings - In a Phase 1b trial involving patients with moderate-to-severe ulcerative colitis (UC), PALI-2108 achieved a 100% clinical response rate, with 40% of patients reaching clinical remission as measured by the modified Mayo Score [5][9] - The treatment resulted in significant downregulation of inflammatory and fibrosis-associated gene expression programs, including suppression of TNF-α, JAK–STAT, NF-κB, MAPK, and TGF-β pathways [5][6] - Histologic improvements were observed alongside reductions in fecal calprotectin and high-sensitivity C-reactive protein (hsCRP) levels, indicating a decrease in inflammation [5][6] Group 2: Mechanism of Action - PALI-2108 is designed for localized delivery to the terminal ileum and colon, where it is bioactivated by bacterial enzymes, allowing for targeted PDE4 inhibition at sites of inflammation while minimizing systemic exposure [7][9] - The prodrug's pharmacological activity was confirmed through RNA sequencing and pathway analyses, which showed localized suppression of inflammatory signaling networks in colonic tissue, with peripheral immune profiles remaining largely unchanged [4][6] Group 3: Safety and Tolerability - The safety profile of PALI-2108 was encouraging, with no serious adverse events reported among the 89 subjects in the study, supporting its potential as a differentiated treatment option for inflammatory bowel diseases [1][9] - The localized pharmacology of PALI-2108 aims to improve tolerability by reducing common side effects associated with systemic PDE4 inhibitors, such as diarrhea, nausea, and headache [7][8] Group 4: Future Development - Palisade Bio is advancing PALI-2108 into a Phase 2 clinical study to evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, with plans for an extension phase to assess maintenance of remission [10]

Core Insights - Bond, Inc. has established a phase 1 commercial agreement valued at approximately $250,000 with a major pharmaceutical company, marking a significant step in its revenue growth strategy [2][3] - The agreement covers 5,000 employees and has the potential to expand the contract value beyond $1 million over time, indicating strong growth prospects for Bond's services [3][4] Revenue Growth - The $250,000 agreement contributes to Bond's Annual Recurring Revenue (ARR) and reflects ongoing traction within large multinational enterprises [5] - Initial enterprise engagements are viewed as foundational relationships that can lead to broader adoption and scalable ARR growth within large organizations [5] Strategic Importance - Executing agreements with global leaders is central to Bond's expansion and revenue growth strategy, aiming to establish a standard for corporate security [6] - The company anticipates that initial coverage will expand to include more employees over time, positioning Bond as a potential global standard for preventative security [6] Versatility and Market Potential - Bond's AI-powered platform is designed to address diverse workforce protection challenges across various employee functions and geographies, enhancing its applicability [7] - The platform's effectiveness, scalability, and affordability contribute to a significant Total Addressable Market (TAM), potentially reaching anyone with a connected device [8] Industry Recognition - Bond has been recognized as a sole supplier of AI-Powered Preventative Personal Security, which streamlines its market entry and reduces competitive tender processes [8] - The company has supported over 1.4 million security service requests, demonstrating its operational effectiveness and growing trust among corporations and public entities [11]

Core Viewpoint - Kyndryl Holdings, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading financial statements and inadequate internal controls during the specified class period [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Brander v. Kyndryl Holdings, Inc., and it allows purchasers of Kyndryl securities from August 7, 2024, to February 9, 2026, to seek lead plaintiff status by April 13, 2026 [1][5]. - The lawsuit alleges that Kyndryl's financial statements were materially misstated and that the company lacked adequate internal controls, which led to an inability to timely file its Quarterly Report for the quarter ended December 31, 2025 [3][4]. Financial and Operational Implications - On February 9, 2026, Kyndryl announced it would be unable to file its Quarterly Report on Form 10-Q on time, citing a review of its cash management practices and internal controls following SEC inquiries [4]. - The company anticipates reporting material weaknesses in its internal control over financial reporting for the fiscal year ended March 31, 2025, and the first two quarters of fiscal year 2026 [4]. - Following the announcement, Kyndryl's stock price fell by 55% [4]. Company Background - Kyndryl operates as a technology services company and IT infrastructure services provider [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6].

Core Viewpoint - Global Water Resources, Inc. has been invited to the 38th Annual ROTH Conference, highlighting its significance in the water resource management sector and its engagement with investors [1][2]. Company Overview - Global Water Resources, Inc. is a leading water resource management company that operates 39 systems providing water, wastewater, and recycled water services, primarily in metropolitan growth corridors around Phoenix and Tucson, Arizona [6]. - The company recycles over 1 billion gallons of water annually, totaling 19.3 billion gallons since 2004, showcasing its commitment to sustainable water management [6]. Conference Participation - The ROTH Conference will feature various formats including on-demand presentations, one-on-one meetings, and industry panels, attracting over 5,000 participants from institutional investors and equity analysts [2]. - CFO and SVP Mike Liebman will engage in one-on-one meetings with analysts and investors on March 23-24, discussing the company's market leadership and ongoing expansion efforts [2][3]. Strategic Focus - The company emphasizes its market leadership in utility consolidation, automation, and water resource management, which are critical for driving revenue growth [3]. - Global Water's Total Water Management (TWM) approach integrates the management of the entire water cycle, enhancing the beneficial use of recycled water and promoting conservation in water-scarce areas [7]. Industry Recognition - Global Water has received multiple awards, including national recognition as a 'Utility of the Future Today' for its superior water reuse practices, reflecting its leadership in the industry [8].

Core Viewpoint - Lakeland Industries, Inc. has appointed Lee D. Rudow to its Board of Directors, effective April 9, 2026, to enhance operational and M&A strategies as the company aims to expand its global footprint in the fire and industrial markets [1][4]. Group 1: Appointment and Experience - Lee D. Rudow brings over 33 years of experience in various leadership roles across startups, private equity-funded, and large industrial companies, currently serving as CEO of Transcat, Inc. for over 14 years [2][3]. - Rudow has a proven track record with 67 consecutive quarters of year-over-year service revenue growth at Transcat, highlighting his capability in driving growth and executing transformative acquisitions [2]. Group 2: Strategic Importance - The appointment of Rudow is seen as timely, providing Lakeland with insights into operational execution and strategic M&A integration, which are crucial for scaling its Fire and Industrial platforms globally [4]. - Rudow expressed his commitment to expanding Lakeland's portfolio and capabilities, aiming to position the company for long-term success in the protective clothing market [4]. Group 3: Company Overview - Lakeland Fire + Safety manufactures a comprehensive line of protective clothing and accessories for various industries, including healthcare and first responders, and offers decontamination, repair, and rental services [5]. - The company sells its products globally, reaching over 50 countries, with significant markets including China, the European Economic Community, Canada, and various regions in Latin America and Asia [5].

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET. A live webcast of the presentatio ...

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th World ADC London Summit, taking place in London, UK, February 23-26, 2026. Plenary/Panel Discussion Details: Panel Discussion: ADC Licensing, Partnering & Investment Session Sutro Participant: Hans-Peter Gerber, Ph.D.Date/Time: Febru ...

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. (“Sentynl”) assumed full responsibility for the development and commercialization ...